Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

2004 ◽  
Vol 40 (12) ◽  
pp. 1878-1885 ◽  
Author(s):  
Lillian Sung ◽  
James R Anderson ◽  
Sarah S Donaldson ◽  
Sheri L Spunt ◽  
William M Crist ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Oncology Group ◽  
Successful Therapy ◽  
Childhood Rhabdomyosarcoma

Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).

1987 ◽  
Vol 5 (6) ◽  
pp. 851-861 ◽  
Author(s):  
L H Baker ◽  
J Frank ◽  
G Fine ◽  
S P Balcerzak ◽  
R L Stephens ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Actinomycin D ◽  
Malignant Tumors ◽  
Soft Tissue Sarcomas ◽  
Comparative Trial ◽  
Phase Iii ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Significant Difference

The term soft tissue sarcoma refers to a large variety of malignant tumors arising in extraskeletal connective tissues that connect, support, and surround discrete anatomic structures. All visceral organs also contain a connective stroma that can undergo malignant transformation. Because of the histological similarities of this group of tumors and their relative rarity, treatment prescriptions for patients that have disseminated disease are most often uniform. In this study, we asked the question whether adding a third drug (cyclophosphamide or actinomycin D) to Adriamycin (Adr [Adria Laboratories, Columbus, OH])-(3,3-dimethyl-1-triazeno)- imidazole-4-carboxamide (DTIC) would improve the response rate and/or survival. A unique feature of this cooperative group clinical trial was the mandatory pathology review of the histological material. All patients of the Southwest Oncology Group between June 1, 1976, and November 17, 1979, who had a biopsy-confirmed diagnosis of a soft tissue sarcoma with convincing clinical or biopsy-documented evidence of metastatic disease were eligible for the study. Patients were randomized to receive (1) Adr, 60 mg/m2 intravenously, day 1, and DTIC, 250 mg/m2 every 3 weeks (104 patients); (2) Adr and DTIC as in (1) and cyclophosphamide, 500 mg/m2, day 1 (112 patients); or (3) Adr and DTIC as in (1) and actinomycin D, 1.2 mg/m2, day 1, (119 patients). There was no statistically significant difference in response rates (33%, 34%, and 24%) (P = .25). Median durations of response were 31 weeks in the Adr-DTIC arm, 26 weeks in the cyclophosphamide-DTIC-Adr arm, and 23 weeks in the Adr-DTIC-Actinomycin D arm (P = .78). Median durations of survival were 37, 42, and 50 weeks, respectively. Again, no statistically significant differences were observed (P = .59). Toxicities from each of these treatment arms were formidable and were equivalent. Prognostic factor analysis showed a prognosis based on bone marrow reserve, sex, and pathology subtype favorable to patients.

scholarly journals Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group

2011 ◽  
Vol 57 (1) ◽  
pp. 76-83 ◽  
Author(s):  
David O. Walterhouse ◽  
Jane L. Meza ◽  
John C. Breneman ◽  
Sarah S. Donaldson ◽  
Andrea Hayes-Jordan ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Local Control ◽  
Oncology Group

scholarly journals The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study

Cancer ◽  
2016 ◽  
Vol 122 (9) ◽  
pp. 1408-1416 ◽  
Author(s):  
Tomoki Nakamura ◽  
Akihiko Matsumine ◽  
Akira Kawai ◽  
Nobuhito Araki ◽  
Takahiro Goto ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Outcome ◽  
Japanese Patients ◽  
Oncology Group ◽  
Musculoskeletal Oncology

scholarly journals Surgical Principles for Children/Adolescents With Newly Diagnosed Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Sarcoma ◽  
2002 ◽  
Vol 6 (4) ◽  
pp. 111-122 ◽  
Author(s):  
David A. Rodeberg ◽  
Charles N. Paidas ◽  
Thom L. Lobe ◽  
Kenneth Brown ◽  
Richard J. Andrassy ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Newly Diagnosed ◽  
Oncology Group

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study

Cancer ◽  
2019 ◽  
Vol 126 (6) ◽  
pp. 1253-1263 ◽  
Author(s):  
Hiroshi Kobayashi ◽  
Shintaro Iwata ◽  
Toru Wakamatsu ◽  
Keiko Hayakawa ◽  
Tsukasa Yonemoto ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Efficacy And Safety ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Musculoskeletal Oncology
Sign in / Sign up

Export Citation Format

Share Document